Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471237 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 564
- Enrollment target
NCT00471237: Clinical Trial Phase 2 study, sponsored by GlaxoSmithKline.
NCT00471237 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 564 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (324% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00471237, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 564 participants
- Enrollment target
Study Summary
This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
Primary Outcome
DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) \*
Interventions
- DRUG Teriparatide
- DRUG Alendronate
- DRUG Ronacaleret
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2007-05-14 |
| Est. Completion | 2008-12-26 |
| Phase | Phase 2 |
Why NCT00471237 stopped before completion
NCT00471237 is an interventional study that assigns participants to a tested intervention. The registered 564 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (324% higher).
The record links to 0 conditions, and to 3 interventions - of which Teriparatide is the first listed.
NCT00471237 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00471237 about?
NCT00471237 is a clinical study titled "A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.". This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
What is the current status of trial NCT00471237?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 564 participants. The study started on 2007-05-14. Estimated completion is 2008-12-26.
What interventions are being tested in trial NCT00471237?
The interventions under investigation include: Teriparatide (DRUG), Alendronate (DRUG), Ronacaleret (DRUG).
Who is sponsoring clinical trial NCT00471237?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00471237's enrollment target sits among peer trials
564 60th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI